EFFECTIVE ONCOLYTIC HERPES SIMPLEX VIRUS VECTOR RETARGETING

Disclosed are recombinant oncolytic Herpes Simplex Virus (oHSV) vectors comprising a non-HSV ligand that specifically binds to a protein present on the surface of a cancer cell. Related nucleic acids, viral stocks, compositions, and methods of killing a cancerous cell are also disclosed. Sont divulg...

Full description

Saved in:
Bibliographic Details
Main Authors INGUSCI, Selene, HALL, Bonnie L, GOINS, William F, MARZULLI, Marco, COHEN, Justus B, GLORIOSO III, Joseph C
Format Patent
LanguageEnglish
French
Published 18.07.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed are recombinant oncolytic Herpes Simplex Virus (oHSV) vectors comprising a non-HSV ligand that specifically binds to a protein present on the surface of a cancer cell. Related nucleic acids, viral stocks, compositions, and methods of killing a cancerous cell are also disclosed. Sont divulgués des vecteurs de virus de l'herpès simplex oncolytiques (oHSV) recombinants comprenant un ligand non-HSV qui se lie spécifiquement à une protéine présente sur la surface d'une cellule cancéreuse. Des acides nucléiques, des huiles virales, des compositions et des procédés d'élimination d'une cellule cancéreuses sont également divulgués.
Bibliography:Application Number: WO2024US11461